Current use and future trends in induction therapy
Author
Source
Saudi Journal of Kidney Diseases and Transplantation
Issue
Vol. 16, Issue 4 (31 Aug. 2005), pp.506-513, 8 p.
Publisher
Saudi Center for Organ Transplantation
Publication Date
2005-08-31
Country of Publication
Saudi Arabia
No. of Pages
8
Main Subjects
Topics
Abstract EN
Induction therapy has been utilized since the late 70s to reorient the immune system at the time of antigen presentation, decrease acute rejection and improve long-term graft survival.
Currently, over 70% of patients undergoing kidney transplantation receive induction therapy.
The current agents include OKT3, polyclonal ant lymphocyte agents (Thymoglobulin being most frequently used), the anti-interleukin-2 receptor monoclonal antibodies daclizumab and basiliximab and Compact 1H.
The current biologic agents are used for short-term therapy although their biologic effects may be prolonged.
The next generation of induction agents is being developed for chronic use in calcineurin inhibitor free and / or steroid-free regimens.
These new biologic agents will be developed to simplify immunosuppression regimens, improve compliance and minimize long term toxicities.
American Psychological Association (APA)
Vincenti, Flavio. 2005. Current use and future trends in induction therapy. Saudi Journal of Kidney Diseases and Transplantation،Vol. 16, no. 4, pp.506-513.
https://search.emarefa.net/detail/BIM-45262
Modern Language Association (MLA)
Vincenti, Flavio. Current use and future trends in induction therapy. Saudi Journal of Kidney Diseases and Transplantation Vol. 16, no. 4 (Aug. 2005), pp.506-513.
https://search.emarefa.net/detail/BIM-45262
American Medical Association (AMA)
Vincenti, Flavio. Current use and future trends in induction therapy. Saudi Journal of Kidney Diseases and Transplantation. 2005. Vol. 16, no. 4, pp.506-513.
https://search.emarefa.net/detail/BIM-45262
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references : p. 512-513
Record ID
BIM-45262